I don't see any mention there of their INGN 241 (The mda-7 gene) of which they have a license from Corixa.
This is a copy from data on Multex:
yahoo.multexinvestor.com
"The mda-7 gene is a tumor suppressor gene that, like p53, has broad potential to induce apoptosis in many types of cancer. The Company has combined the mda-7 gene with its adenoviral vector system to form INGN 241.
Its pre-clinical trials have determined that INGN 241 suppresses growth of many cancer cells, including those of the breast, lung, colon, prostate and central nervous system, while not affecting growth of normal cells. Because INGN 241 kills cancer cells, even if other tumor suppressor genes, including p53 or p16, are not functioning properly, it appears that mda-7 functions via a novel mechanism of tumor suppression.
Introgen's pre-clinical trials also indicate that in addition to its known activity as a tumor suppressor gene, the mda-7 gene may also stimulate the body's immune system to protect it against cancer, thereby offering the potential of providing an added advantage in treating various cancers because it may attack cancer using two different mechanisms.
The mda-7 gene may work effectively as a radiation sensitizer to make several types of human cancer cells more susceptible to the anti-cancer effect of radiation therapy as indicated in its pre-clinical work.
The Company has also published the results of a pre-clinical trial indicating INGN 241 may suppress the growth in-vivo of non-small-cell lung cancer through apoptosis, or programmed cell death, in combination with anti-angiogenesis.
Introgen has an exclusive license to the mda-7 gene for gene therapy applications from Corixa Corporation.
It is conducting a Phase I clinical trial using INGN 241 testing safety and mechanism of action in approximately 15 patients with solid tumors.
Its pre-clinical program with INGN 241 has included research at The University of Texas M. D. Anderson Cancer Center, Columbia University and Corixa Corporation".
On the long run, it seems that INGN 241 may have larger capabilities than ADVEXIN
RAGL
Bernard |
